This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

MDT Insights: When to choose ZEPATIER® (elbasvir/grazoprevir) as a treatment option for your HCV patients with CKD?

Patient Case Study: An HCV patient with CKD

Prescribing Information

Length: 07:05

Dr Ahmed Elsharkawy
Consultant Hepatologist, Queen Elizabeth Hospital, Birmingham

Eleri Lougher
Hepatitis C ODN Lead Pharmacist, Queen Elizabeth Hospital, Birmingham

Sally Bufton
ODN Nurse Manager, Queen Elizabeth Hospital, Birmingham

This promotional video is fully funded and filmed by MSD.

More information about ZEPATIER® (elbasvir/grazoprevir):

Supporting documentation

GB-ZEP-00063 | Date of Preparation: March 2019